Roivant Sciences: Brepocitinib And Roadmap Still Underpriced [Seeking Alpha]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Seeking Alpha
ROIV focuses on autoimmune and rare-disease drug programs. Recent promising Phase 3 data for DM with Brepocitinib have helped the stock appreciate. Brepocitinib could tap into a sizeable TAM over time, and its NDA filing for DM is expected by 1H2026. Plus, it can target NIU and CS. ROIV's other Vants add optionality in IgG-mediated autoimmune diseases and pulmonary hypertension. Genevant's LNP patent litigation is a wildcard. Overall, I still believe ROIV's long-term prospects remain undervalued, which is why I reiterate my “Buy” rating at these levels. Md Saiful Islam Khan/iStock via Getty Images Roivant Sciences Ltd. ( ROIV ) is a late-stage autoimmune and rare-disease company that currently has three subsidiaries called Vants: 1) Priovant, 2) Immunovant, and 3) Pulmovant. Priovant is working on Brepocitinib in Phase 3 for dermatomyositis (DM) and has an NDA targeted for 1H2026. Immunovant is developing IMVT-1402 as a This article was written by Analyst's Disclosure:
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Vivek Ramaswamy's Net Worth Has Nearly Doubled While He's Running For Ohio Governor [Forbes]Forbes
- Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ROIV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at Citigroup Inc. from $25.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]Seeking Alpha
ROIV
Earnings
- 11/10/25 - Beat
ROIV
Sec Filings
- 11/24/25 - Form 4
- 11/24/25 - Form 4
- 11/21/25 - Form 4
- ROIV's page on the SEC website